Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Glyn Johnson

Showing results (61-70 of 63) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 63 results.
Journal of Neurosurgery|October 7, 2008
Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survivalAshwatha Narayana, Patrick Kelly, John Golfinos, et al.
European Journal of Radiology|February 10, 2009
Relative cerebral blood volume measurements of low-grade gliomas predict patient outcome in a multi-institution settingGisele B Caseiras, Sophie Chheang, James Babb, et al.
Alzheimer'S & Dementia (New York, N. Y.)|November 15, 2018
The Cognitive Ageing, Nutrition and Neurogenesis (CANN) trial: Design and progressMichael A Irvine, Andrew Scholey, Rebecca King, et al.
Pageof 7

Showing results (61-70 of 63) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 63 results.
Journal of Neurosurgery|October 7, 2008
Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survivalAshwatha Narayana, Patrick Kelly, John Golfinos, et al.
European Journal of Radiology|February 10, 2009
Relative cerebral blood volume measurements of low-grade gliomas predict patient outcome in a multi-institution settingGisele B Caseiras, Sophie Chheang, James Babb, et al.
Alzheimer'S & Dementia (New York, N. Y.)|November 15, 2018
The Cognitive Ageing, Nutrition and Neurogenesis (CANN) trial: Design and progressMichael A Irvine, Andrew Scholey, Rebecca King, et al.
Pageof 7